Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Pillar Biosciences Closes $29.7M Series C Financing Round

Pillar Biosciences Closes $29.7M Series C Financing Round

May 12, 2020
|
staff reporter

NEW YORK – Cancer diagnostic testing firm Pillar Biosciences announced Tuesday that it has closed a $29.7 Series C preferred stock financing round led by ORI Healthcare Fund. It also announced CE marking for its Onco/Reveal Dx lung and colon cancer in vitro diagnostic assay.

The Natick, Massachusetts-based assay developer said it will use the funds to accelerate expansion of its clinical and research-use next-generation sequencing panels and to expand its global commercial reach.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Russia Vaccine Approval Raises Concerns

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

Numbers Needed

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

PNAS Papers on Sarcoma Fusion Effects, Transfer RNA Changes in Colon Cancer, TB-T2D Interactions

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Move Away From Basic Research?

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Aug
26
Featured Webinar

Resolving Complex Haplotypes Implicated in Alzheimer’s and Other Neurodegenerative Diseases

Sponsored by
Bionano Genomics

Alzheimer’s disease is genetically complex with no meaningful therapies or pre-symptomatic disease diagnostics. 

What's Popular?

In Molecular Diagnostics

  1. Helix Gets FDA Emergency Use Authorization for NGS-Based COVID-19 Test

  2. Illumina Sees Expanding Sequencing Market in COVID-19 Response, Despite Short-Term Woes

    Premium

  3. Guardant Health Colorectal Cancer Early-Detection Test Progresses Despite Pandemic Challenges

    Premium

  4. Guardant Health CDx Wins FDA Approval for First Liquid Biopsy NGS Tumor Profiling Assay

  5. Adaptive Biotechnologies Q2 Revenues Fall 5 Percent, Beat Analyst Estimates

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.